Results 171 to 180 of about 1,262,540 (308)

Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers. [PDF]

Gynecol Oncol Rep
Bastin N, Petrie H, Robinson M, Javid A, Lane R, Boucher T, Brown AJ, Prescott LS, Phillips E, Alvarez RD, Crispens M, Stone CA.   +11 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Bevacizumab-Based Therapy Is Associated with Prolonged Progression-Free Survival in Patients with Peritoneal Mucinous Metastatic Colorectal Cancer. [PDF]

J Clin Med
Can S, Çakıcı V, Kahveci GB, Eroğlu Ş, Tok B, Uygun G, Özer E, Çırak Y, Gökmen İ.   +8 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Disturbance of functional connectivity in patients with low grade glioma is associated with worse progression-free survival. [PDF]

Neurooncol Adv
Stoecklein VM, Wunderlich S, Weller J, Papazov B, Suvak S, Katzendobler S, Schmutzer-Sondergeld M, Schichor C, Thon N, Von Baumgarten L, Kalasauskas D, Harter PN, Ricke J, Liebig T, Ringel F, Stoecklein S.   +15 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility

South Asian Journal of Cancer
Santosh Kumar Swain, Lalatendu Moharana, Ghanashyam Biswas, Lipsita Samantaray, Ayush Dubey, Reetu Singhal, Bhavya Inimerla, Antara Sanyal, Swati Sucharita Mohanty, Soumya Surath Panda   +9 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Impact of Prolonged Surgical Waiting Time on 5-Year Progression-Free Survival in Patients With Endometrial Cancer. [PDF]

J Obstet Gynaecol Res
Pulsawat A, Noothong S, Sirimusika N.
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source